Tilray's Stock Is as Cheap as It's Been Since 2020. 1 Thing to Know Before You Buy.
Many valuation metrics suggest that Tilray Brands (NASDAQ: TLRY) is a screaming buy right now. Just look at the cannabis stock's price-to-sales ratio. Shares traded above 2.4 times sales roughly 12 months ago, yet now trade at just 0.6 times sales despite growing revenue.This looks like a great entry point for growth investors. But before you jump in, there's one critical piece of information you should understand.Tilray's cannabis pharmaceutical business has grown by leaps and bounds over the years. Five years ago, the company was generating only $400 million in annual revenue. Since then, sales have more than doubled. But there's a problem: Profitability remains elusive, even as sales growth has stagnated.Continue reading
Many valuation metrics suggest that Tilray Brands (NASDAQ: TLRY) is a screaming buy right now. Just look at the cannabis stock's price-to-sales ratio. Shares traded above 2.4 times sales roughly 12 months ago, yet now trade at just 0.6 times sales despite growing revenue.
This looks like a great entry point for growth investors. But before you jump in, there's one critical piece of information you should understand.
Tilray's cannabis pharmaceutical business has grown by leaps and bounds over the years. Five years ago, the company was generating only $400 million in annual revenue. Since then, sales have more than doubled. But there's a problem: Profitability remains elusive, even as sales growth has stagnated.
